Latest news - Novo Nordisk
2024年11月1日 · Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
1 天前 · Novo Nordisk News and Updates. 12/9/2024. Novo Nordisk has received European approval to acquire Catalent, a U.S. drug manufacturer responsible for producing a large portion of Novo Nordisk’s ...
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
2024年11月6日 · Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief...
Company announcements & press releases - Novo Nordisk
Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial - Forbes
2024年9月11日 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk A/S (NVO) Latest Stock News & Headlines
Get the latest Novo Nordisk A/S (NVO) stock news and headlines to help you in your trading and investing decisions.
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust
1 天前 · Still, several pharma companies bristled at the news of the deal. Eli Lilly CEO David Ricks voiced his concern in the company’s second-quarters earnings call in August, saying that they “rely on one of the Catalent sites for GLP-1 and other diabetes production,” a space in which Novo Nordisk is the other major player. Ricks highlighted ...
Novo Holdings’ acquisition of Catalent gains EC approval - Yahoo …
1 天前 · Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for its acquisition of Catalent. Catalent is expected to leverage Novo ...
Novo Nordisk Reports Headline Results From Part 1 Of ESSENCE …
2024年11月1日 · (RTTNews) - Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic...
News details - Novo Nordisk
2024年5月30日 · News & media; Contact us; News. ... Thu, 30 May 2024 10:00:00 -0400. Novo Nordisk escalates legal actions to safeguard patients from potentially harmful compounded “semaglutide” drugs. Novo Nordisk filed 9 new legal proceedings against medical spas, weight loss clinics, pharmacies, and other companies for unlawful marketing and sales of ...
跳至内容